Oncology
Advanced Malignancy
0
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Advanced Malignancy is an early-stage landscape with 0 programs across 3 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GW Pharmaceuticals Ltd, Jazz Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
12
clinical trials
Completed9 · 75%
Unknown status3 · 25%
Clinical Trials
Trial Activity
12 trials
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
Unknown status·—·Phase 1·NCT03217669·15 enrolled
Everolimus and Capecitabine in Patients With Advanced Malignancy
Unknown status·—·Phase 1/2·NCT01079702·35 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)